Once a red-hot ingredient, cannabidiol (CBD) seeks to retake the supplement spotlight after a rocky 2020, led by new hemp-derived phytocannabinoids and other derivatives. Market saturation and regulatory uncertainty has hampered industry growth, but research on the endocannabinoid system is connecting CBD intake and various health issues, from inflammation to mood and beyond. Other minor phytocannabinoids identified for more in-depth research include cannabigerol (CBG), cannabinol (CBN) and cannabichromene (CBC).